Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Natalizumab treatment leads to an increase in circulating CXCR3-expressing B cells.
Example Based Lesion Segmentation.
Differential Expression of Glucocorticoid Receptor Noncoding RNA Repressor Gas5 in Autoimmune and Inflammatory Diseases.
MicroRNAs associated with the pathogenesis of multiple sclerosis.
Hemoglobins as new players in multiple sclerosis: metabolic and immune aspects.
Antigen dynamics govern the induction of CD4(+) T cell tolerance during autoimmunity.
Are electrophysiological criteria useful in distinguishing childhood demyelinating neuropathies?
Screening and characterization of molecules that modulate the biological activity of IFNs-I.
Current and emerging treatment of multiple sclerosis.
Functional Predictors Of Physical Activity Levels In Patients With Multiple Sclerosis: 2571 Board #94 June 3, 9: 30 AM - 11: 00 AM.
ActiGait implantable drop foot stimulator in multiple sclerosis: a new indication.
Distribution-based estimates of minimum clinically important difference in cognition, arm function and lower body function after slow release-fampridine treatment of patients with multiple sclerosis.
Acute Disseminated Encephalomyelitis.
Observational data: Understanding the real MS world.
Factitious Graves' disease due to biotin immunoassay interference - A case and review of the literature.
Re: The effect of venous anatomy on the morphology of multiple sclerosis lesions: a susceptibility-weighted imaging study.
T cell cytokine signatures: Biomarkers in pediatric multiple sclerosis.
CEACAM1 mediates B cell aggregation in central nervous system autoimmunity.
Neuroendothelial NMDA receptors as therapeutic targets in experimental autoimmune encephalomyelitis.
Benefit-Risk of Therapies for Relapsing-Remitting Multiple Sclerosis: Testing the Number Needed to Treat to Benefit (NNTB), Number Needed to Treat to Harm (NNTH) and the Likelihood to be Helped or Harmed (LHH): A Systematic Review and Meta-Analysis.
Proteomics and transcriptomics of peripheral nerve tissue and cells unravel new aspects of the human schwann cell repair phenotype.
Effect of interferon-β1α therapy on multiple sclerosis based on gadolinium-enhancing or active T2 magnetic resonance imaging outcomes: a meta-analysis.
MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study.
Interleukin 2 activates brain microvascular endothelial cells resulting in destabilization of adherens junctions.
Acute demyelination following radiotherapy for glioma: a cautionary tale.
Pages
« first
‹ previous
…
846
847
848
849
850
851
852
853
854
…
next ›
last »